Last reviewed · How we verify
NCT00322894
Expanded Breast Cancer Registry and Tissue Repository
trial in Breast Cancer in 500 participants. Completed in 31 March 2025.
2 August 2016
Quick facts
| Lead sponsor | New Mexico Cancer Research Alliance |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 16 February 2006 |
| Primary completion | 2 August 2016 |
| Estimated completion | 31 March 2025 |
| Sites | 1 location across United States |
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
New Mexico Cancer Research Alliance — full company profile →
Who can join
18 and older, any sex, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Expanded Breast Cancer Registry and Tissue Repository Research Team (EBCR-RT) is comprised of University of Mexico Comprehensive Cancer Center faculty and staff whose goals are to improve the outcomes and quality of life of patients with breast cancer, and ultimately to eradicate and cure breast cancer. One focus of the EBCR-RT is the creation an infrastructure that can potentially be adopted as a model for a statewide registry and tissue repository for the discovery of biomarkers for this disease. The goals of the EBCR are: 1. To register patients diagnosed with breast cancer and information relevant to their diagnosis (such as stage, grade, hormone receptor status, etc), treatment (surgery, radiation, chemotherapy, hormone therapy, etc), and survivorship (Quallity of Life, etc). 2. To collect relevant demographics including age, menopausal status, race/ethnicity, body mass index (BMI), place of residence, behaviors (smoking, alcohol intake, etc) 3. To establish a paired tumor tissue and blood sample for each relevant time-point (as defined in the protocol), which will be stored in the Tissue Bank Shared Resource Facility for future hypothesis-driven research.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The rs4646 and rs12592697 Polymorphisms in <i>CYP19A1</i> Are Associated with Disease Progression among Patients with Breast Cancer from Different Racial/Ethnic Backgrounds.
Armamento-Villareal R, Shah VO, Aguirre LE, Meisner AL, et al · · 2016 · cited 5× · PMID 27994616 · DOI 10.3389/fgene.2016.00211
Verify or expand the search:
- PubMed search for NCT00322894
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other New Mexico Cancer Research Alliance trials
Trials by the same sponsor.
- NCT07436793 — Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial · Phase 2 · not yet recruiting
- NCT06260332 — Physical Activity Intervention for the Improvement of Pain in Young, Hispanic Breast Cancer Survivors · NA · active not recruiting
- NCT06207864 — Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing · NA · recruiting
- NCT05176743 — Food Insecurity in Oncology · NA · completed
- NCT04259762 — Enhancing Cancer Prevention and Control Pathways-Native Health Initiative · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00322894 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by New Mexico Cancer Research Alliance
- Last refreshed: 22 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00322894.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing